RNA-seq of 4 naive GBM cell lines upon dexamethasone (0.1 uM) treatment

The introduction in the 1960s of the glucocorticoids-based therapy for the management of the vasogenic edema forming in brain tumour patients is considered as a revolution in the history of neurosurgery. Since then, although it is impossible to deny the ability of glucocorticoids to reduce mortality and morbidity of brain tumour patients worldwide, many scientific papers have highlighted the controversial effects that they can exert on glioma cells, for instance in terms of enhanced proliferation and interference with chemotherapeutics drugs. Among synthetic glucocorticoids, the most widely used is Dexamethasone (Dex). Using 4 different Glioblastoma Patient-Derived Xenograft (PDX) cell lines, we treated them with or without Dex 0.1 µM in order to look at the drug-related changes in the transcriptome of the cells. Each experiment has produced 8 samples (1 CTR sample and 1 DEX-treated sample for each cell line) and the experiment has been repeated 3 times, thus giving a total of 24 samples.